آتزولیزومب (Persian Wikipedia)
Analysis of information sources in references of the Wikipedia article "آتزولیزومب" in Persian language version.
refsWebsite
Global rank
Persian rank
1st place
1st place
low place
low place
low place
low place
1,684th place
533rd place
low place
low place
cancer.gov
- "Checkpoint Inhibitor Use Changed for Bladder Cancer". National Cancer Institute. 26 July 2018.
curetoday.com
- Concurrent Tecentriq Adds First Survival Benefit Seen in Small Cell Lung Cancer in 20 Years | https://www.curetoday.com/articles/concurrent-tecentriq-adds-first-survival-benefit-seen-in-small-cell-lung-cancer-in-20-years بایگانیشده در ۳۱ دسامبر ۲۰۱۹ توسط Wayback Machine
doi.org
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
drugs.com
- FDA Professional Drug Information for Tecentriq.
fda.gov
fda.gov
- "FDA approves new, targeted treatment for bladder cancer" (Press release). U.S. Food and Drug Administration (FDA). 18 May 2016. Retrieved 20 May 2016.
This article incorporates text from this source, which is in the public domain. - "FDA approves new treatment for non-small cell lung cancer". U.S. Food and Drug Administration (FDA). 18 October 2016. Retrieved 18 May 2016. This article incorporates text from this source, which is in the public domain.
accessdata.fda.gov
- "Tecentriq (atezolizumab) Injection". U.S. Food and Drug Administration (FDA). 21 June 2016. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
healio.com
- Today, HemOnc; June 25; 2017. "Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer". www.healio.com.
{{cite web}}: CS1 maint: numeric names: فهرست نویسندگان (link)
immuno-oncologynews.com
nih.gov
pubmed.ncbi.nlm.nih.gov
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
web.archive.org
- "Tecentriq (atezolizumab) Injection". U.S. Food and Drug Administration (FDA). 21 June 2016. Archived from the original on 5 December 2019. Retrieved 4 December 2019.
- Concurrent Tecentriq Adds First Survival Benefit Seen in Small Cell Lung Cancer in 20 Years | https://www.curetoday.com/articles/concurrent-tecentriq-adds-first-survival-benefit-seen-in-small-cell-lung-cancer-in-20-years بایگانیشده در ۳۱ دسامبر ۲۰۱۹ توسط Wayback Machine